IP Library Granted Patent US 7,718,375
Granted Patent B2
US 7,718,375 · App. 10/083,476 · Granted May 18, 2010

Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,375
App. No.
10/083,476
Granted
May 18, 2010
Kind
B2
Abstract

The present invention relates to modifying rapid immunochromatographic (“ICT”) tests for the detection of characteristic carbohydrate antigens of bacteria that are known to be causative of otitis media and respiratory diseases in children under the age of approximately 12 years. The test modifications involve either (1) reducing the total amount of antibodies to the carbohydrate antigen employed in each test, (2) adding at least one fixed “scrub” line located just prior to the capture line in the sample flow path to the prepared ICT test strip to “scrub” out an identical amount of target antigen from all bodily fluid test samples obtained from both colonized but otherwise healthy children and diseased children, or (3) combinations of (1) and (2).

Claims (8)

1. A method for detecting a symptomatic Streptococcus pneumoniae infection in a human subject of age 12 years or less comprising:

applying, to a sample receiving zone at an end of a bibulous test strip, a urine sample obtained from the human subject of age 12 years or less;

allowing the urine sample to flow laterally along the bibulous test strip;

mobilizing tagged purified antibodies capable of binding the C-polysaccharide antigen of Streptococcus pneumoniae , the tagged purified antibodies having been present immediately ahead of the sample receiving zone on the bibulous test strip and rendered flowable by contact with the urine sample, to form a mixture comprising the urine sample and the mobilized tagged purified antibodies;

allowing the binding of the tagged purified antibodies and the C-polysaccharide antigen, to form conjugates of the tagged purified antibodies and the C-polysaccharide antigen in the mixture;

allowing the mixture comprising the conjugates of the tagged purified antibodies and the C-polysaccharide antigen to flow further along the bibulous test strip;

allowing the binding of the conjugates of the tagged purified antibodies and the C-polysaccharide antigen to scrub line antibodies specific for the conjugates of the tagged purified antibodies and the C-polysaccharide antigen, the scrub line antibodies having been immobilized in at least one scrub line along the bibulous test strip;

allowing the mixture comprising the conjugates of the tagged purified antibodies and the C-polysaccharide antigen to flow downstream of the at least one scrub line; and allowing the binding of capture line antibodies specific for the conjugates of the tagged purified antibodies and the C-polysaccharide antigen, the capture line antibodies having been immobilized in a capture line downstream of the at least one scrub line, to the conjugates of the tagged purified antibodies and the C-polysaccharide antigen, wherein color formation in the downstream capture line resulting from the binding of the conjugates of the tagged purified antibodies and the C-polysaccharide antigen to the immobilized capture line antibodies specific for the conjugates of the tagged purified antibodies and the C-polysaccharide antigen is indicative of the symptomatic Streptococcus pneumoniae infection in the subject.

Assignments (4)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →